ArticleFrontiers in pharmacology2023
Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 29 citations in OpenAlex.
- Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real-World Analysis of WHO Pharmacovigilance Data.Clinical pharmacology and therapeutics · 2026Article
- Chemical Motifs Associated with FAERS-Derived Severe Cutaneous Adverse Reaction Disproportionality Signals: An Interpretable Pharmacovigilance-Driven Cheminformatics Study.International journal of molecular sciences · 2026Article
- A Comprehensive Disproportionality Analysis of Drug-Related Head Injury Reports Using the FAERS Database.Brain and behavior · 2026Article
- Severe cutaneous adverse reactions linked to medications in children and adolescents: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.International journal of clinical pharmacy · 2026Article
- Risk of drug eruption associated with the use of tetracyclines, macrolides, and fluoroquinolones: real-world evidence from a pharmacovigilance study utilizing the FDA adverse event reporting system.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- Intensive Adverse Drug Reaction Monitoring Program Improves Detection of Phenytoin-Induced Adverse Drug Reactions.Patient preference and adherence · 2026Article
- Differential risk signals of cutaneous adverse drug reactions among β-lactam antibiotics: ceftriaxone shows increased signals for SJS/TEN in clinical and real-world cohorts.Frontiers in medicine · 2026Article
- An international scoping review of epidemiologic studies on severe cutaneous adverse reactions.The World Allergy Organization journal · 2026Article
- Real-World Data on Severe Cutaneous Adverse Reactions to Drugs.Pharmaceuticals (Basel, Switzerland) · 2025Article
- HLA-B Alleles With Shared Peptide Binding Specificities Define Global Risk of Co-trimoxazole-Induced Severe Cutaneous Adverse Drug Reactions.The journal of allergy and clinical immunology. In practice · 2025Article
- Pharmacovigilance of drug-induced cataract using the FDA Adverse Event Reporting System.Scientific reports · 2025Article
- Pharmacovigilance study of drug-induced eye movement disorder based on FDA adverse event reports from 2004 to 2024.Scientific reports · 2025Article
- Drug-Induced Serious Cutaneous Reactions in Hospitalized Patients: A Cross-Sectional Study.Journal of clinical medicine · 2025Article
- Severe cutaneous adverse drug reactions due to antituberculosis drugs and their management.Northern clinics of Istanbul · 2025Article
- Severe cutaneous adverse reactions to anti-osteoporosis drugs: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database and a review of published cases.Frontiers in pharmacology · 2025Article
- Assessment of drug-related migraine in a real-world large-scale database.Frontiers in pharmacology · 2025Article
- Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology.Allergy · 2025Review
- Stevens-Johnson Syndrome in a Patient on Concomitant Treatment with Levetiracetam and Trimethoprim/Sulfamethoxazole.The American journal of case reports · 2024Article
- Drug-induced retinal vein occlusion: a disproportionality analysis from the FDA adverse event reporting system (2004-2023).Frontiers in pharmacology · 2024Article
- Camrelizumab-induced immune-related toxic epidermal necrolysis in lung adenocarcinoma: a case report and literature review.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.